Hua‐Ling Tsai

1.0k total citations
44 papers, 494 citations indexed

About

Hua‐Ling Tsai is a scholar working on Hematology, Oncology and Surgery. According to data from OpenAlex, Hua‐Ling Tsai has authored 44 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 12 papers in Oncology and 10 papers in Surgery. Recurrent topics in Hua‐Ling Tsai's work include Hematopoietic Stem Cell Transplantation (17 papers), Acute Myeloid Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). Hua‐Ling Tsai is often cited by papers focused on Hematopoietic Stem Cell Transplantation (17 papers), Acute Myeloid Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). Hua‐Ling Tsai collaborates with scholars based in United States, Austria and Uganda. Hua‐Ling Tsai's co-authors include Richard J. Jones, Ravi Varadhan, David W. Eisele, Margueritta El Asmar, Eleni M. Rettig, Farhoud Faraji, Carole Fakhry, Kenneth R. Cooke, Amy E. DeZern and Philip Imus and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hua‐Ling Tsai

44 papers receiving 492 citations

Peers

Countries citing papers authored by Hua‐Ling Tsai

Since Specialization

Citations

This map shows the geographic impact of Hua‐Ling Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua‐Ling Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua‐Ling Tsai more than expected).

Fields of papers citing papers by Hua‐Ling Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua‐Ling Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua‐Ling Tsai. The network helps show where Hua‐Ling Tsai may publish in the future.

Co-authorship network of co-authors of Hua‐Ling Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Hua‐Ling Tsai. A scholar is included among the top collaborators of Hua‐Ling Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua‐Ling Tsai. Hua‐Ling Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies 2024 ·Blood Advances ·Philip Imus, Sergiu Paşca, Hua‐Ling Tsai, Yosra Aljawai, Kenneth R. Cooke, Jeremy Walston, Christopher D. Gocke, Ravi Varadhan, Richard J. Jones, Lukasz P. Gondek	4
2	Association of Cardiovascular Disease in Patients with Mycosis Fungoides and Sézary Syndrome Compared to a Matched Control Cohort 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Priyanka Kumar, Hua‐Ling Tsai, Ravi Varadhan, Sima Rozati	1
3	Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia 2023 ·Leukemia Research ·Tania Jain, (unknown), W. Brian Dalton, Sergiu Paşca, Hua‐Ling Tsai, Christopher D. Gocke, Lukasz P. Gondek, Rena R. Xian, Michael J. Borowitz, Mark J. Levis	4
4	Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease 2023 ·Leukemia & lymphoma ·Khaled Sanber, (unknown), Hua‐Ling Tsai, (unknown), Jonathan Webster, Ivana Gojo, Gabriel Ghiaur, Gabrielle T. Prince, Lukasz P. Gondek, Benjamin D. Smith, Mark J. Levis, Amy E. DeZern, Alexander J. Ambinder, W. Brian Dalton, Tania Jain	3
5	Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide 2023 ·Blood ·(unknown), (unknown), Hua‐Ling Tsai, Michael P. Randall, (unknown), Ravi Varadhan, Alexander J. Ambinder, Amy E. DeZern, Theodoros Karantanos	1
6	Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function 2023 ·Transplantation and Cellular Therapy ·(unknown), Hua‐Ling Tsai, Ravi Varadhan, (unknown), Richard J. Jones, Alexander J. Ambinder	1
7	859 ESOPREDICT: A CLINICALLY APPLICABLE PROGNOSTIC ASSAY FOR RISK STRATIFICATION OF PATIENTS WITH BARRETT'S ESOPHAGUS 2023 ·Gastroenterology ·(unknown), (unknown), Hua‐Ling Tsai, Yulan Cheng, Andrew Kalra, Ke Ma, Simran Jit, Ali H. Zaidi, David Lu, (unknown), Lisa Kann, (unknown), Stephen J. Meltzer	1
8	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source 2022 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Hua‐Ling Tsai, (unknown), Ephraim J. Fuchs, Lode J. Swinnen, Suman Paul, Javier Bolaños‐Meade, Leo Luznik, Philip Imus, Syed Abbas Ali, Tania Jain, Alexander J. Ambinder, Amy E. DeZern, Carol Ann Huff, Christian B. Gocke, Ravi Varadhan, Nina D. Wagner‐Johnston, Richard J. Jones, Richard F. Ambinder	6
9	HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age 2022 ·Blood Advances ·Alexander J. Ambinder, Tania Jain, Hua‐Ling Tsai, Mary M. Horowitz, Richard J. Jones, Ravi Varadhan	15
10	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy 2022 ·Leukemia & lymphoma ·Theodoros Karantanos, Hua‐Ling Tsai, Lukasz P. Gondek, Amy E. DeZern, Gabriel Ghiaur, W. Brian Dalton, Ivana Gojo, Gabrielle T. Prince, Jonathan Webster, Alexander J. Ambinder, B. Douglas Smith, Mark J. Levis, Ravi Varadhan, Richard J. Jones, Tania Jain	8
11	Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice 2022 ·Virology ·(unknown), Margaret Wong, Hua‐Ling Tsai, Hao Wang, Reinhard Kirnbauer, Andrew J. Griffith, Paul F. Lambert, Richard B.S. Roden	3
12	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial 2022 ·Practical Radiation Oncology ·Colin Hill, Lauren M. Rosati, Hao Wang, Hua‐Ling Tsai, Jin He, Amy Hacker‐Prietz, Daniel A. Laheru, Lei Zheng, (unknown), Vincent Bernard, Dung T. Le, Timothy M. Pawlik, Matthew J. Weiss, Amol Narang, Joseph M. Herman	10
13	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide 2021 ·Blood Advances ·Amy E. DeZern, (unknown), Hua‐Ling Tsai, Philip Imus, Kenneth R. Cooke, Ravi Varadhan, Richard J. Jones	53
14	The Art of Donor Selection: Donor Age and Relationship in NMA Haplo BMT 2021 ·Transplantation and Cellular Therapy ·Amy E. DeZern, (unknown), Hua‐Ling Tsai, Ravi Varadhan, Philip Imus, Richard J. Jones	1
15	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN) 2020 ·Blood ·Theodoros Karantanos, Hua‐Ling Tsai, Lukasz P. Gondek, Mark J. Levis, Margaret M. Showel, Amy E. DeZern, Ivana Gojo, Ravi Varadhan, Richard J. Jones, Tania Jain	1
16	Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study 2019 ·Clinical Cancer Research ·Zhixiong Wang, Swetha Kambhampati, Yulan Cheng, Ke Ma, Cem Şimşek, Alan H. Tieu, John Abraham, Xi Liu, Vishnu Prasath, Mark D. Duncan, Alejandro Stark, Alexander Y. Trick, Hua‐Ling Tsai, Hao Wang, Yulong He, Mouen A. Khashab, Saowanee Ngamruengphong, Eun Ji Shin, Tza‐Huei Wang, Stephen J. Meltzer	42
17	The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status 2018 ·Cancer ·Farhoud Faraji, Eleni M. Rettig, Hua‐Ling Tsai, Margueritta El Asmar, (unknown), David W. Eisele, Carole Fakhry	87
18	Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer 2018 ·Cancer ·Anya M. Litvak, (unknown), Stuart D. Russell, Hua‐Ling Tsai, Gary L. Rosner, Stacie C. Jeter, Deborah K. Armstrong, Leisha A. Emens, John H. Fetting, Antonio C. Wolff, (unknown), Vered Stearns, Roisín M. Connolly	61
19	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor‐directed therapies 2015 ·The Prostate ·Rosa Nadal, Hua‐Ling Tsai, Victoria J. Sinibaldi, Channing J. Paller, Emmanuel S. Antonarakis, (unknown), Michael A. Carducci, Mario A. Eisenberger	16
20	Tumor size and presence of calcifications on ultrasonography are pre‐operative predictors of lymph node metastases in patients with papillary thyroid cancer 2011 ·Journal of Surgical Oncology ·(unknown), (unknown), Hua‐Ling Tsai, Helina Somervell, Sara I. Pai, Ralph P. Tufano, Christopher B. Umbricht, Jeanne Kowalski, Alan P.B. Dackiw, Martha A. Zeiger	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact